Abstract
AIDS-related Kaposi sarcoma (AIDS-KS), a common malignancy in Kenya is associated with high morbidity and mortality. AIDS-KS is treated using bleomycin and vincristine (BV) plus or minus doxorubicin in most low resource settings, with response rates ranging from 24.8 to 87%. Survival in low resource settings has not been well documented. We report the three-year survival in a cohort of seventy patients referred to Moi Teaching and Referral Hospital (MTRH). Study participants are part of a randomized phase IIA trial on the use of gemcitabine compared to bleomycin plus vincristine for the treatment of Kaposi sarcoma after combination antiretroviral therapy (cART) in Western Kenya. All patients were followed for three years in MTRH. Survival was determined by three monthly physical examination and analysed using Kaplan-Meier method, while possible determinants of survival such as baseline characteristics, type of chemotherapy, initial CD4 counts, age at enrolment, gender and early response to chemotherapy were analysed using univariate and multivariate Cox regression. Participants were aged between 19 and 70 years with 56% being male. The median CD4 count was 224 cells/μl, median duration of HIV diagnosis was 12.0 months and media...Continue Reading
References
Dec 16, 1994·Science·Y ChangP S Moore
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GillM E Ross
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E KrownJ Huang
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W NorthfeltD H Henry
Jan 29, 2003·The Journal of Infectious Diseases·Ludo LavreysJoan K Kreiss
May 17, 2003·The Journal of Infectious Diseases·Sam M MbulaiteyeRobert J Biggar
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guglielmo NastiUNKNOWN AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian
Jan 18, 2007·The Oncologist·Timothy CooleyWayne Rackoff
Mar 11, 2010·Oncology·R Matthew StrotherPatrick J Loehrer
Jun 22, 2010·Cancer·Mary CianfroccaJoseph A Sparano
Sep 25, 2010·The Journal of Infectious Diseases·Benon BiryahwahoSam M Mbulaiteye
Nov 26, 2010·PloS One·Warren PhippsCorey Casper
Mar 8, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Anisa MosamHoosen M Coovadia
Feb 2, 2013·Archives of Pathology & Laboratory Medicine·Oana Radu, Liron Pantanowitz
Dec 3, 2013·Conflict and Health·Suzanne GoodrichKara Wools-Kaloustian
Jan 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark BowerMark Nelson
Jul 4, 2015·International Journal of Cancer. Journal International Du Cancer·Anne KorirMax Parkin
Dec 30, 2015·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Rodgers LupiaFeng-Jen Tsai
Apr 16, 2016·PloS One·Nader Kim El-MallawanyParth S Mehta
Jan 21, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Fred OkukuWarren Phipps
Aug 23, 2017·PloS One·Kathryn E RoyseElizabeth Y Chiao
Oct 13, 2017·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·M M SengayiJ Bohlius
Feb 2, 2018·Infectious Agents and Cancer·Vini FardhdianiMatthew E Coldiron
Jun 9, 2018·The Pan African Medical Journal·Eliane RohnerJulia Bohlius
Sep 23, 2018·Journal of Global Oncology·Naftali W BusakhalaPatrick J Loehrer